Your browser doesn't support javascript.
loading
ALDH2(E487K) mutation increases protein turnover and promotes murine hepatocarcinogenesis.
Jin, Shengfang; Chen, Jiang; Chen, Lizao; Histen, Gavin; Lin, Zhizhong; Gross, Stefan; Hixon, Jeffrey; Chen, Yue; Kung, Charles; Chen, Yiwei; Fu, Yufei; Lu, Yuxuan; Lin, Hui; Cai, Xiujun; Yang, Hua; Cairns, Rob A; Dorsch, Marion; Su, Shinsan M; Biller, Scott; Mak, Tak W; Cang, Yong.
Affiliation
  • Jin S; Agios Pharmaceuticals, Inc., Cambridge, MA 02139; shengfang.jin@agios.com tmak@uhnres.utoronto.ca cangyong@zju.edu.cn.
  • Chen J; Life Sciences Institute and Innovation Center for Cell Signaling Network, Zhejiang University, Hangzhou, Zhejiang 310058, China; Department of General Surgery, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, China;
  • Chen L; Oncology Business Unit and Innovation Center for Cell Signaling Network, WuXi AppTec Co., Ltd., Shanghai 200131, China;
  • Histen G; Agios Pharmaceuticals, Inc., Cambridge, MA 02139;
  • Lin Z; Oncology Business Unit and Innovation Center for Cell Signaling Network, WuXi AppTec Co., Ltd., Shanghai 200131, China;
  • Gross S; Agios Pharmaceuticals, Inc., Cambridge, MA 02139;
  • Hixon J; Agios Pharmaceuticals, Inc., Cambridge, MA 02139;
  • Chen Y; Agios Pharmaceuticals, Inc., Cambridge, MA 02139;
  • Kung C; Agios Pharmaceuticals, Inc., Cambridge, MA 02139;
  • Chen Y; Oncology Business Unit and Innovation Center for Cell Signaling Network, WuXi AppTec Co., Ltd., Shanghai 200131, China;
  • Fu Y; Life Sciences Institute and Innovation Center for Cell Signaling Network, Zhejiang University, Hangzhou, Zhejiang 310058, China;
  • Lu Y; Oncology Business Unit and Innovation Center for Cell Signaling Network, WuXi AppTec Co., Ltd., Shanghai 200131, China;
  • Lin H; Department of General Surgery, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, China;
  • Cai X; Department of General Surgery, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, China;
  • Yang H; Agios Pharmaceuticals, Inc., Cambridge, MA 02139;
  • Cairns RA; The Campbell Family Institute for Breast Cancer Research, Ontario Cancer Institute, Princess Margaret Cancer Centre, Toronto, ON, Canada M5G 2C1.
  • Dorsch M; Agios Pharmaceuticals, Inc., Cambridge, MA 02139;
  • Su SM; Agios Pharmaceuticals, Inc., Cambridge, MA 02139;
  • Biller S; Agios Pharmaceuticals, Inc., Cambridge, MA 02139;
  • Mak TW; The Campbell Family Institute for Breast Cancer Research, Ontario Cancer Institute, Princess Margaret Cancer Centre, Toronto, ON, Canada M5G 2C1 shengfang.jin@agios.com tmak@uhnres.utoronto.ca cangyong@zju.edu.cn.
  • Cang Y; Life Sciences Institute and Innovation Center for Cell Signaling Network, Zhejiang University, Hangzhou, Zhejiang 310058, China; Oncology Business Unit and Innovation Center for Cell Signaling Network, WuXi AppTec Co., Ltd., Shanghai 200131, China; shengfang.jin@agios.com tmak@uhnres.utoronto.ca can
Proc Natl Acad Sci U S A ; 112(29): 9088-93, 2015 Jul 21.
Article in En | MEDLINE | ID: mdl-26150517
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Aldehyde Dehydrogenase / Liver Neoplasms / Mutation Type of study: Prognostic_studies / Risk_factors_studies Limits: Animals / Humans Language: En Journal: Proc Natl Acad Sci U S A Year: 2015 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Aldehyde Dehydrogenase / Liver Neoplasms / Mutation Type of study: Prognostic_studies / Risk_factors_studies Limits: Animals / Humans Language: En Journal: Proc Natl Acad Sci U S A Year: 2015 Document type: Article Country of publication: United States